skip to primary navigationskip to content


Figure 1. Clinical responses of advanced metastatic melanoma patients to immune checkpoint inhibitor therapy. Progression-free survival (RECIST criteria) of patients with advanced melanoma at a median follow-up of 2 years in all patients assigned to treatment. Responses of individuals randomised to either anti-CTLA-4 (ipilimumab), or combined anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) treatment groups are shown. Data from Hodi et al., Lancet Oncol 2016)
Full-size image: 109 KB | View imageView Download imageDownload

Advice for staff and students at the University and Colleges on novel coronavirus (COVID-19). The University is continually monitoring latest Public Health England and government advice about the virus.

Read more